PRE Stock Overview
Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Prenetics Global Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.05 |
52 Week High | US$16.20 |
52 Week Low | US$3.25 |
Beta | -0.087 |
1 Month Change | -16.67% |
3 Month Change | -31.47% |
1 Year Change | -71.88% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.53% |
Recent News & Updates
Shareholder Returns
PRE | US Healthcare | US Market | |
---|---|---|---|
7D | -14.0% | 1.1% | 0.2% |
1Y | -71.9% | 9.4% | 28.1% |
Return vs Industry: PRE underperformed the US Healthcare industry which returned 9.5% over the past year.
Return vs Market: PRE underperformed the US Market which returned 28.8% over the past year.
Price Volatility
PRE volatility | |
---|---|
PRE Average Weekly Movement | 11.1% |
Healthcare Industry Average Movement | 7.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRE's share price has been volatile over the past 3 months.
Volatility Over Time: PRE's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 400 | Danny Yeung | https://www.prenetics.com |
Prenetics Global Limited operates as a diagnostics and genetic testing company in Hong Kong and the United Kingdom. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring device that offers COVID-19 testing solutions for professional use and home use. The company’s products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; ACTOnco, a comprehensive test that helps clinicians choose the optimal treatment for all major solid tumors; ACTDrug+, a screening test that checks for 40 cancer genes to map drug options and provide treatment strategy options; ACTLung, a test focused on biomarkers associated with lung cancer for targeted therapy; ACTFusion, a test that decodes 13 fusion genes and more than 350 transcripts to map drug options; and ACTCerebra, a genomic profiling service for solid tumors.
Prenetics Global Limited Fundamentals Summary
PRE fundamental statistics | |
---|---|
Market cap | US$48.67m |
Earnings (TTM) | -US$17.63m |
Revenue (TTM) | US$279.64m |
0.2x
P/S Ratio-2.8x
P/E RatioIs PRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PRE income statement (TTM) | |
---|---|
Revenue | US$279.64m |
Cost of Revenue | US$146.55m |
Gross Profit | US$133.10m |
Other Expenses | US$150.72m |
Earnings | -US$17.63m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.47 |
Gross Margin | 47.60% |
Net Profit Margin | -6.30% |
Debt/Equity Ratio | 0% |
How did PRE perform over the long term?
See historical performance and comparison